Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $6.5800 (-0.15%) ($6.5800 - $6.5800) on Thu. Sep. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.66% (three month average) | RSI | 53 | Latest Price | $6.5800(-0.15%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.5% a day on average for past five trading days. | Weekly Trend | AUTL declines -1.9% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(53%) ARKG(48%) ARKK(48%) IBUY(48%) IWO(48%) | Factors Impacting AUTL price | AUTL will decline at least -1.83% in a week (0% probabilities). VIXM(-33%) VXX(-29%) SHY(-21%) TLT(-18%) XLU(-15%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.83% (StdDev 3.66%) | Hourly BBV | -0.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $6.7 | 5 Day Moving Average | $6.65(-1.05%) | 10 Day Moving Average | $6.91(-4.78%) | 20 Day Moving Average | $6.7(-1.79%) | To recent high | -14% | To recent low | 23.8% | Market Cap | $344m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |